Takashi Okamura
Overview
Explore the profile of Takashi Okamura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
902
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamasaki S, Hashiguchi M, Yoshida-Sakai N, Jojima H, Osaki K, Okamura T, et al.
Hematol Rep
. 2024 Nov;
16(4):714-723.
PMID: 39584925
Background: The development of newer agents, including anti-CD38 monoclonal antibodies (mAbs), has significantly improved overall survival (OS) in patients with relapsed or refractory multiple myeloma (RRMM). However, the treatment of...
2.
Shima M, Suzuki N, Nishikii H, Amano K, Ogawa Y, Kobayashi R, et al.
Thromb Haemost
. 2024 Aug;
PMID: 39134043
Background: Primary analysis of the phase III AGEHA study suggested a favorable benefit-risk profile for emicizumab prophylaxis in patients with acquired hemophilia A (PwAHA); however, only patients undergoing immunosuppressive therapy...
3.
Matsumoto T, Murakami Y, Yoshida-Sakai N, Katsuchi D, Kanazawa K, Okamura T, et al.
Int J Mol Sci
. 2024 May;
25(9).
PMID: 38731802
5-azacytidine (AZA), a representative DNA-demethylating drug, has been widely used to treat myelodysplastic syndromes (MDS). However, it remains unclear whether AZA's DNA demethylation of any specific gene is correlated with...
4.
Yamaguchi M, Takaki Y, Yamasaki Y, Oya S, Nakamura T, Morishige S, et al.
Rinsho Ketsueki
. 2024 Mar;
65(2):90-94.
PMID: 38448004
A 62-year-old woman was diagnosed as a hemophilia A carrier (factor VIII activity 35%) on preoperative examination of an ovarian tumor. A total of 35,600 units of recombinant factor VIII...
5.
Shima M, Amano K, Ogawa Y, Yoneyama K, Ozaki R, Kobayashi R, et al.
J Thromb Haemost
. 2023 Jan;
21(3):534-545.
PMID: 36696195
Background: Emicizumab is a bispecific antibody that mimics the cofactor function of activated factor (F) VIII. It prevents bleeds in patients with congenital hemophilia A regardless of the inhibitor status;...
6.
Osaki K, Sogabe Y, Seki R, Nakamura T, Morishige S, Oku E, et al.
Kurume Med J
. 2022 Sep;
67(2.3):83-89.
PMID: 36123027
We investigated the molecular basis of factor VII (FVII) deficiency in a Japanese patient and identified compound heterozygous mutations. Factor VII activity and antigen levels in the patient were less...
7.
Yoshida-Sakai N, Oe K, Kimura Y, Ureshino H, Nomiyama K, Hashiguchi M, et al.
Ann Hematol
. 2022 Feb;
101(6):1383-1385.
PMID: 35194669
No abstract available.
8.
Nakamura T, Morodomi Y, Kanaji S, Okamura T, Nagafuji K, Kanaji T
Thromb Res
. 2021 Dec;
209:80-83.
PMID: 34894532
No abstract available.
9.
Matsumoto S, Yamada E, Nakajima Y, Yamaguchi N, Okamura T, Yajima T, et al.
World J Clin Cases
. 2021 Jan;
9(1):163-169.
PMID: 33511180
Background: Hypoglycemia due to non-insulin-producing tumors is referred to as non-islet cell tumor hypoglycemia (NICTH). As NICTH is a rare lesion, the natural course of NICTH is not well understood....
10.
Suga T, Sato K, Ohyama T, Matsui S, Kobayashi T, Tojima H, et al.
World J Hepatol
. 2020 Aug;
12(7):350-362.
PMID: 32821334
Background: Sodium glucose cotransporter 2 (SGLT2) inhibitors are newly developed oral antidiabetic drugs. SGLT2 is primarily expressed in the kidneys and reabsorbs approximately 90% of the glucose filtered by the...